| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df874e3cf88adba3792dc9d5b5776180
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35e38db230cc5450a4bd956b36620e99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c930c1a3fcc9a93dc304ab4a77bd0ea3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a60649a09a47690f2c5082c03fbc2212 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate |
2018-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_298ab9534af28d5502256200accff0a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6457fd507ab64b1532abf331395ea16e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa0a1b48933530f3f02fe0733f4b6cb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9191473f89b2cc3ea13bb79583fd8aaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77a6a09e507912e61a8228f73ce7879b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e6d2f7d5415db888540c10b6f20a4f6 |
| publicationDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018134260-A1 |
| titleOfInvention |
Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| abstract |
The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. Using MPN mouse model and clonogenic methyl-cellulose cultures of patient progenitors, the inventors demonstrate that combining ARS with IFN improves most of the benefits provided by IFN alone during MPN treatment. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound. |
| priorityDate |
2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |